MTX

Research output: Contribution to journalReview article

1 Citation (Scopus)

Abstract

Methotrexate is an anchor drug in the management of rheumatoid arthritis (RA). MTX monotherapy is as effective as TNF inhibitor (TNFi) monotherapy, and can prevent joint destruction in 70% of Japanese early RA patients. Also, MTX in combination with TNFi is superior to MTX monotherapy or TNFi monotherapy. Many high quality clinical studies have proved that MTX should be added to biological agents irrespective of their mode of action in inducing remission. However, it also causes hepatotoxicity, bone marrow suppression, nausea, and so on. A question arises if the dose of MTX to maintain remission could be reduced once remission is achieved. The optimal dose and usage of methotrexate remains to clarify.

Original languageEnglish
Pages (from-to)944-947
Number of pages4
JournalNihon rinsho. Japanese journal of clinical medicine
Volume74
Issue number6
Publication statusPublished - 2016 Jun 1

Fingerprint

Methotrexate
Rheumatoid Arthritis
Biological Factors
Nausea
Joints
Bone Marrow
Pharmaceutical Preparations
Clinical Studies

ASJC Scopus subject areas

  • Medicine(all)

Cite this

MTX. / Kaneko, Yuko.

In: Nihon rinsho. Japanese journal of clinical medicine, Vol. 74, No. 6, 01.06.2016, p. 944-947.

Research output: Contribution to journalReview article

Kaneko, Yuko. / MTX. In: Nihon rinsho. Japanese journal of clinical medicine. 2016 ; Vol. 74, No. 6. pp. 944-947.
@article{4e894e027f0742328231bc8b2d341f3a,
title = "MTX",
abstract = "Methotrexate is an anchor drug in the management of rheumatoid arthritis (RA). MTX monotherapy is as effective as TNF inhibitor (TNFi) monotherapy, and can prevent joint destruction in 70{\%} of Japanese early RA patients. Also, MTX in combination with TNFi is superior to MTX monotherapy or TNFi monotherapy. Many high quality clinical studies have proved that MTX should be added to biological agents irrespective of their mode of action in inducing remission. However, it also causes hepatotoxicity, bone marrow suppression, nausea, and so on. A question arises if the dose of MTX to maintain remission could be reduced once remission is achieved. The optimal dose and usage of methotrexate remains to clarify.",
author = "Yuko Kaneko",
year = "2016",
month = "6",
day = "1",
language = "English",
volume = "74",
pages = "944--947",
journal = "Nihon rinsho. Japanese journal of clinical medicine",
issn = "0047-1852",
publisher = "Nipponrinsho Co., Inc.",
number = "6",

}

TY - JOUR

T1 - MTX

AU - Kaneko, Yuko

PY - 2016/6/1

Y1 - 2016/6/1

N2 - Methotrexate is an anchor drug in the management of rheumatoid arthritis (RA). MTX monotherapy is as effective as TNF inhibitor (TNFi) monotherapy, and can prevent joint destruction in 70% of Japanese early RA patients. Also, MTX in combination with TNFi is superior to MTX monotherapy or TNFi monotherapy. Many high quality clinical studies have proved that MTX should be added to biological agents irrespective of their mode of action in inducing remission. However, it also causes hepatotoxicity, bone marrow suppression, nausea, and so on. A question arises if the dose of MTX to maintain remission could be reduced once remission is achieved. The optimal dose and usage of methotrexate remains to clarify.

AB - Methotrexate is an anchor drug in the management of rheumatoid arthritis (RA). MTX monotherapy is as effective as TNF inhibitor (TNFi) monotherapy, and can prevent joint destruction in 70% of Japanese early RA patients. Also, MTX in combination with TNFi is superior to MTX monotherapy or TNFi monotherapy. Many high quality clinical studies have proved that MTX should be added to biological agents irrespective of their mode of action in inducing remission. However, it also causes hepatotoxicity, bone marrow suppression, nausea, and so on. A question arises if the dose of MTX to maintain remission could be reduced once remission is achieved. The optimal dose and usage of methotrexate remains to clarify.

UR - http://www.scopus.com/inward/record.url?scp=84979097866&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84979097866&partnerID=8YFLogxK

M3 - Review article

C2 - 27311183

AN - SCOPUS:84979097866

VL - 74

SP - 944

EP - 947

JO - Nihon rinsho. Japanese journal of clinical medicine

JF - Nihon rinsho. Japanese journal of clinical medicine

SN - 0047-1852

IS - 6

ER -